Go Back

Immunic
Immunic is currently pursuing three development programs. These include:
More Details
- the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of small molecule inhibitors of the enzyme dihydroorotate dehydrogenase, or DHODH;
- the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated, or RORγt, an immune cell-specific isoform of RORγ;
- and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium.
These product candidates are being developed to address diseases such as multiple sclerosis, psoriasis and gastrointestinal diseases.